MedinCell S.A. Logo

MedinCell S.A.

MEDCL | PA

Overview

Corporate Details

ISIN(s):
FR0004065605
LEI:
969500R79U6PXCL2FF46
Country:
France
Address:
3 RUE DES FRERES LUMIERE, 34830 JACOU
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

MedinCell S.A. is a clinical and commercial-stage pharmaceutical company that develops a portfolio of long-acting injectable products across various therapeutic areas. The company's core activity involves combining its proprietary BEPO® technology with known active pharmaceutical ingredients to create innovative, extended-release treatments. MedinCell's business model focuses on developing these therapeutic solutions and licensing them to partners for commercialization. The company aims to optimize the efficiency and global accessibility of medical treatments, thereby enhancing and safeguarding patient health worldwide.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for MedinCell S.A.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-17 17:45
Annual / Quarterly Financial Statement
Inside Information / News release on accounts, results
English 405.2 KB
2025-06-17 17:45
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 395.7 KB
2025-06-10 18:00
Report Publication Announcement
Inside Information / Other news releases
English 185.6 KB
2025-06-10 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 192.0 KB
2025-06-06 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 183.7 KB
2025-05-28 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 183.1 KB
2025-05-28 18:00
Regulatory News Service
Inside Information / Other news releases
English 156.6 KB
2025-05-28 17:45
Regulatory News Service
Inside Information / Other news releases
English 220.0 KB
2025-05-28 17:45
Earnings Release
Informations privilégiées / Autres communiqués
French 218.7 KB
2025-05-21 18:36
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 183.5 KB
2025-05-07 15:12
Earnings Release
Inside Information / Other news releases
English 227.6 KB
2025-05-07 15:12
Earnings Release
Informations privilégiées / Autres communiqués
French 217.5 KB
2025-04-22 18:11
Regulatory News Service
Informations privilégiées / Autres communiqués
French 194.3 KB
2025-04-22 18:11
Legal Proceedings Report
Inside Information / Other news releases
English 208.5 KB
2025-04-15 19:48
Regulatory News Service
Informations privilégiées / Autres communiqués
French 283.2 KB

Automate Your Workflow. Get a real-time feed of all MedinCell S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for MedinCell S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-05-02 N/A Other Sell 60,000 600,006.00 EUR

Peer Companies

Company Country Ticker View
Oncodesign Precision Medicine S.A Logo
Develops therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiopharmaceuticals like Radspherin® for localized cancer treatment.
Norway OCIN
OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden ONCOZ
Onxeo Logo
Developing precision therapies for complex diseases using a proprietary single-domain antibody platform.
France ALONX
OPTIBIOTIX HEALTH PLC Logo
Develops microbiome-modulating ingredients and supplements to manage chronic lifestyle diseases.
United Kingdom OPTI
Oramed Pharmaceuticals Inc. Logo
Developing oral drug delivery systems to replace injections, like an oral insulin capsule.
Israel ORMP
Oryzon Genomics S.A. Logo
Advancing epigenetic therapeutics for oncology and central nervous system disorders.
Spain ORY
OSE Immunotherapeutics Logo
Developing first-in-class immunotherapies for immuno-oncology and immuno-inflammation.
France OSE
Ovoca Bio Plc Logo
Clinical-stage biopharma developing novel treatments for female sexual dysfunction.
Ireland OVXA
OXFORD BIODYNAMICS PLC Logo
Develops precision blood tests using 3D genomics for cancer diagnosis and therapy guidance.
United Kingdom OBD